SP-0202 (GBP410): A 21-Valent Pneumococcal Conjugate Vaccine Candidate

1. Introduction

1.1 Overview of SP-0202 (GBP410)

SP-0202 is an investigational 21-valent pneumococcal conjugate vaccine (PCV21) candidate currently in late-stage clinical development.[1] Also identified by the development code GBP410, and sometimes referred to as "Next Gen PCV - Sanofi" or "Next-generation pneumococcal conjugate vaccine - Sanofi/SK Bioscience", this vaccine aims to prevent invasive pneumococcal disease (IPD) and other infections caused by the bacterium Streptococcus pneumoniae.[2] Pneumococcal infections, including pneumonia, meningitis, sepsis, and otitis media, represent a significant global health burden, particularly affecting young children and older adults.[4] Existing pneumococcal vaccines have substantially reduced disease incidence, but the emergence of non-vaccine serotypes and the desire for broader protection drive the development of next-generation vaccines like SP-0202/GBP410.[4] By incorporating antigens against 21 distinct pneumococcal serotypes, SP-0202/GBP410 seeks to offer expanded protection compared to currently available vaccines.[1]

1.2 Developers and Collaboration